Abstract
This research service covers the pharmaceutical industry development pipeline for diabetes mellitus in the United States, with 2005 as the base year. Included are both the products projected to enter the market by the end of the forecast coverage period in 2012, as well as products entering the market in 2005 that correspond to the in-depth discussion drug classes. The focus of this piece is on pipeline technology developments and has greater focus on: GLP-1 Agonists, DPP-IV Inhibitors; PPAR Modulators; and Pulmonary Insulin. Also discussed are pipeline developments in other areas of oral antidiabetic drugs, injectables, and insulins other than pulmonary. Product Analysis charts are included for those products in Phase III clinical trials.
Table of Contents
1 EXECUTIVE SUMMARY
- Executive Summary
- Introduction
2 MARKET INTRODUCTION
- Research Scope and Methodology
- Scope and Segmentation
- Research Methodology
- Diabetes Overview
- Introduction
- Types of Diabetes
- Prevalence
- Incidence
- Current Treatment
- Pipeline Competitive Analysis
- Introduction
- Key Pipeline Companies
- Areas of Opportunity
3 GLP-1 AGONISTS
- Introduction
- GLP-1 Agonist Dynamics
- GLP-1 Agonists Pipeline Analysis
- Byetta - Amylin & Eli Lilly
- GLP-1 Agonist Pipeline
4 PULMONARY INSULIN
- Introduction
- Pulmonary Insulin Dynamics
- Pulmonary Insulin Analysis
- Exubera - Pfizer & Nektar
- Pulmonary Insulin Pipeline
5 DPP-IV INHIBITORS
- Introduction
- DPP-IV Dynamics
- DPP-IV Pipeline Analysis
- Pipeline Analysis
6 PPAR MODULATORS
- Introduction
- PPAR Dynamics
- PPAR Pipeline Analysis
- PPAR Pipeline
- Discontinued PPAR Modulators
7 OTHER PIPELINE EFFORTS
- Introduction
- Other Development Efforts
- Pipeline Overviews
- Other Insulin Pipeline
- Other OAD Pipeline
- Other IAD Pipeline
8 APPENDIX
- Decision Support Databases
- Incidence of Diabetes
- Prevalence of Diabetes
- Diabetes Prevalence as a Percentage of Total Population
- Diabetes Foot Ulcer Prevalence as a Percentage of Total Population
- Total Population
